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Abstract
The Onchocerca ochengi adult implant and Brugia malayi microfilariemic Severe-Combined
Immunodeficient (SCID) mouse models are validated screens to measure macrofilaricidal
and microfilaricidal activities of candidate onchocerciasis drugs. The purpose of this study
was to assess whether 5 daily sub-cutaneous (s.c.) injections of standard flubendazole
(FBZ) suspension (10mg/kg), a single s.c. injection (10mg/kg) or 5 daily repeated oral doses
of FBZ amorphous solid dispersion (ASD) formulation (0.2, 1.5 or 15mg/kg) mediated
macrofilaricidal efficacy against O. ochengi male worms implanted into SCID mice. The
direct microfilaricidal activity against circulating B. malayi microfilariae of single dose FBZ
ASD formulation (2 or 40 mg/kg) was also evaluated and compared against the standard
microfilaricide, ivermectin (IVM). Systemic exposures of FBZ/FBZ metabolites achieved fol-
lowing dosing were measured by pharmacokinetic (PK) bioanalysis. At necropsy, five
weeks following start of FBZ SC injections, there were significant reductions in burdens of
motile O. ochengi worms following multiple injections (93%) or single injection (82%). Fur-
ther, significant proportions of mice dosed following multiple injections (5/6; 83%) or single
injection (6/10; 60%) were infection negative (drug-cured). In comparison, no significant
reduction in recovery of motile adult O. ochengi adult worms was obtained in any multiple-
oral dosage group. Single oral-dosed FBZ did not mediate any significant microfilaricidal
activity against circulating B. malayi mf at 2 or 7 days compared with >80% efficacy of single
dose IVM. In conclusion, multiple oral FBZ formulation doses, whilst achieving substantial
bioavailability, do not emulate the efficacy delivered by the parenteral route in vivo against
adult O. ochengi. PK analysis determined FBZ efficacy was related to sustained systemic
drug levels rather than achievable Cmax. PK modelling predicted that oral FBZ would have
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to be given at low dose for up to 5 weeks in the mouse model to achieve a matching effica-
cious exposure profile.
Author summary
Onchocerciasis, caused by the filarial parasitic worm, Onchocerca volvulus, is a major
cause of infection-related blindness and skin disease and is targeted for elimination. Cur-
rent drugs are not optimal in all patient populations and a short-course cure would accel-
erate elimination. Flubendazole is used to treat intestinal worms in humans. The current
oral formulation is not well absorbed into the blood. Flubendazole treatment has mediated
curative efficacy in onchocerciasis patients when given as an injection but also causes
adverse reactions at the injection site. In this study, we tested whether a new oral formula-
tion of flubendazole with improved absorption could selectively kill Onchocerca adult par-
asites compared with circulating larval filarial parasites, using immunodeficient mouse
models. Whilst injections of flubendazole mediated high levels of efficacy, five-day oral
treatment, at a range of doses, did not emulate this curative effect. Oral flubendazole also
did not significantly affect levels of microfilariae in the blood. After comparing levels of
flubendazole in the blood following injection versus oral treatment, we conclude that a
long duration, low dose of the oral formulation, for 5 weeks, would be needed to match
the exposure of the drug following injection.
Introduction
Onchocerciasis remains a severe public health problem despite the sustained efforts of mass
drug administration (MDA) programs aimed at eliminating this vector-borne, parasitic
neglected tropical disease [1–3]. Elicited by the filarial nematode Onchocerca volvulus and
transmitted by black flies of the genus Simulium, it is endemic in much of Sub-Saharan Africa,
as well as more limited foci in Brazil, Venezuela, and The Yemen with 37 million people
infected [4, 5]. The pathology associated with onchocerciasis ranges from troublesome skin
itching, skin disease (onchodermatitis), to blindness, which is caused by a sclerosing ocular
keratitis that affects 0.8 million individuals and is the second cause of infectious blindness after
trachoma [5–7]. Onchocercal disease is induced by death of migratory larval microfilariae
(mf), causing liberation of inflammatory stimuli including the endosymbiont Wolbachia and
inflammatory recruitment of granulocytes [8, 9]. The debilitating symptoms of onchodermati-
tis and river blindness also cause great economic losses in endemic areas [10].
Onchocerciasis is targeted for elimination as a public health problem [11, 12]. The African
Program for Onchocerciasis Control (APOC) and, latterly, The Extended Special Project for
Elimination of NTDs (ESPEN) were created to this end [13]. The current strategy involves the
use of the microfilaricidal drug, ivermectin (IVM, Mectizan). Ivermectin targets mf produced
by mating adult filariae, and is deployed using an MDA strategy [2, 3, 14, 15].
Because IVM is microfilaricidal yet lacks significant macrofilaricidal activity, it must be
administered repetitively and with very high population coverage over an extended period of
time in order to break transmission. This is predicted as at least twelve annual treatment
rounds [2, 3, 16].
The undeniable success of MDA programs can be seen in certain country settings where a
decline in prevalence has been recorded as well as a reduction in disease burden [17].
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However, in other countries, the limitation of MDA programs for onchocerciasis within Africa
is evident and several persistent areas of infection remain, possibly due to emerging resistance
[18–21]. Also, in certain regions, poor adherence to IVM treatment is apparent and associated
with sustained skin infection prevalence. Where onchocerciasis MDA overlaps with health dis-
tricts endemic for the related filaria, Loa loa, low adherence to treatment is linked to the per-
ceived risk of IVM induced severe neurological adverse reactions [22, 23]. Therefore, if
onchocerciasis elimination targets within the ambitious 2030 United Nations Sustainable
Development Goal timeframes are to be achieved, there is an urgent need to implement alter-
native strategies.
For these reasons, a safe, chemotherapeutic agent that will selectively kill adult O. volvulus
worms without mediating rapid ‘ivermectin-like’ microflaricidal activity, is urgently needed,
preferably with a short treatment period of less than 7 days. Typically, the most practical and
safest administration of a field agent is through oral dosage [24].
Flubendazole (FBZ), is a benzimidazole anthelmintic that acts through interfering with the
equilibrium among tubulin subunits and elicits macrofilaricidal effects by preferentially bind-
ing to nematode tubulin [25]. FBZ was initially developed for use against gastrointestinal para-
sitic nematodes in livestock [26], but was later approved for use in humans in the treatment of
soil-transmitted helminths with high efficacy [27–29]. The drug has also been shown to be
highly efficacious in experimental models of lymphatic filariasis when administered subcuta-
neously [24, 30, 31] as well as in a human trial treating onchocerciasis [32]. Onchocerca
ochengi, a cattle parasite, is the closest phylogenetic relative to the target human parasite, O.
volvulus. Recently, multiple subcutaneous injections of FBZ has mediated >90% efficacy
against O. ochengi in severe-combined immunodeficient (SCID) mice [33]. Unfortunately, the
approved formulation has a very limited bioavailability when orally administered. When
administered parenterally, severe reactions around the subcutaneous injection site were
reported in the clinical trial [32].
Efforts have been made to develop a re-formulation of FBZ that would enable oral dosing
[24, 34, 35]. The purpose of this study was to assess the oral efficacy of a new formulation of
FBZ (Janssen Pharmaceutica) in SCID mice implanted with adult male O. ochengi parasites.
Single versus multiple subcutaneous doses of standard FBZ suspension were also compared. In
addition, the selective toxicity of oral FBZ against adult Onchocerca versus bloodborne mf in
circulation was tested in a Brugia malayi SCID mouse infusion model. The primary goal was
to identify regimens that cause minimally 90% reduction in adult Onchocerca parasite num-
bers in treated animals compared to untreated controls.
Methods
Animals
Male CB.17 (BALB/c congenic) SCID mice, 5–6 weeks of age, were purchased from Charles
River Europe. Mice were shipped to either The Research Foundation for Tropical Diseases and
the Environment (REFOTDE), Buea, Cameroon (for O. ochengi studies) or University of Liv-
erpool Biological Services Unit (UoL BSU), UK (for the B. malayi study) in filter topped boxes.
Mice were maintained in individually ventilated caging (IVC) with HEPA filtered air system
(Tecniplast, UK) with autoclaved bedding and fed / watered ad libitum with UV sterilised
appropriate certified rodent diet (irradiated chow) / autoclaved water. Following a 7 days accli-
matization period, SCID mice were 7–8 weeks of age at initiation of studies.
Mongolian gerbils were originally purchased from Charles River and a colony bred at UoL
BSU under specific-pathogen-free (SPF) conditions.
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Ethics statement
All experiments carried out in Cameroon were approved by the Animal Care Committee,
REFOTDE. All experiments undertaken in UK were approved by institutional Animal Welfare
Ethics Review Boards of University of Liverpool and Liverpool School of Tropical Medicine
and were undertaken in accordance with national legislation (Home Office Project Licence 30/
2974).
Isolation of male O. ochengi
O. ochengi positive cattle from Adamawa Province, Cameroon, were selected by nodule palpa-
tion in the umbilical region. The O. ochengi positive cattle were transported to the South West
Province and maintained in pastureland local to REFOTDE, Buea. Individual infected cattle
were slaughtered at a local abattoir. For each cow, the umbilical region was excised and trans-
ported to REFOTDE within 2 hours after slaughter. Skin samples were washed and rinsed in
sterile PBS, the hair removed by shaving and onchocercomata (nodules) were excised from the
dermal surface using sterile scalpels and forceps. Nodules were immediately placed in com-
plete sterile RPMI medium (10% foetal calf serum, 100U/ml penicillin, 0.1mg/ml streptomycin
and 2.5μg/ml amphotericin B), the capsular surface of the nodule incised and gentle pressure
applied to liberate adult stage O. ochengi parasites. Nodules were incubated in petri dishes in
complete medium for 4h, 37˚C, 5% CO2 to allow adult male parasites to migrate from nodule
tissue. Intact, motile male O. ochengi parasites were washed in sterile complete RPMI and incu-
bated overnight 37˚C, 5% CO2.
Experimental implantation with O. ochengi
SCID mice were weighed and ear marked, anaesthetised by a combination of ketamine and
medetomidine (1/10μg/kg subcutaneous (SC)), administered with prophylactic antibiotic pen-
icillin G, SC, shaved on the upper left abdomen and swabbed with iodine. Anaesthetised mice
were arranged on sterile drapes on top of heat pads, and a small incision made through both
skin and abdominal wall with sterile surgical instruments. Fifteen motile O. ochengi male
worms were picked from cultures using sterile forceps and implanted into the peritoneal cavity
with 0.5ml RPMI. Efficiency of implantation was confirmed by verifying absence of male
worms in the dish and on forceps by washing with medium. Mice were sutured through the
abdomen and skin and iodine re-applied, administered with an α2-antagonist (atipamezole)
and placed on heat pads until recovered. Post-surgery and recovery from anaesthesia, mice
were housed in original family groups in IVCs, monitored regularly.
B. malayi microfilarial purification and experimental infection
B. malayi microfilariae (Bmmf) were isolated from the peritoneal cavity of experimentally
infected Mongolian gerbils by peritoneal washing in RPMI medium containing 100U/ml peni-
cillin, 0.1mg/ml streptomycin (RPMI+PS) using a sterile catheter drain, under anaesthesia, as
previously described [33]. Motile Bmmf were purified from host cells by PD-10 desalting
sephadex column (GE Healthcare) at room temperature (rt), washed 3x in RPMI+P/S rt, resus-
pended in known volume of RPMI+PS, maintained at 37˚C, 5%CO2 whilst density was enu-
merated by microscopy. Motile Bmmf were adjusted to 1.25x106/ml in RPMI+PS 37˚C.
Subsequently, 200μl aliquots were loaded into 1ml low dead space syringes with 29 gauge nee-
dles and maintained at 37˚C.
Preclinical testing of oral flubendazole as an Onchocerciasis macrofilaricide
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B. malayi microfilarial experimental infection
Mice were placed in small animal thermal cages at 37˚C for 5 minutes to dilate the tail vein.
Motile Bmmf were infused via the lateral tail vein with manual restraint in a maximum volume
of 200μl. Efficiency of inoculation was confirmed by needle washout and enumeration of mf
retained in the needle / syringe. Efficiency of inoculation ((inoculation number—needle wash-
out number) / inoculation number x100) was>96% in all animals infused.
Drug preparation
All compounds and vehicles were provided by Janssen and the formulations were prepared on
site at REFOTDE, Buea or shipped prepared to Liverpool. The vehicle for FBZ Bend 1/9 oral
(OR) suspensions (JNJ-161941-AAA/HPMC AS-HG 1/9) was 0.5% w/v Methocel A4M (Pre-
mium) in demineralized water. The vehicle for the FBZ SC suspension was 0.5% w/v HEC
(Hydroxyethylcellulose) in demineralized water + 0.1% Tween80. Briefly, oral FBZ suspen-
sions were prepared from the supplied Spray Dried Drug and first homogenised in deminera-
lised water using a Polytron disperser then made up to volume with Methocel, a different
formulation was prepared for each treatment group to keep the dosing volume constant. The
subcutaneous suspension was first homogenised in demineralised water + 0.1% Tween80
using a Polytron disperser then made up to volume with HEC.
Drug treatment randomisation and blinding
Following surgical implantation with O. ochengi or infusion with Bmmf, mice were ear-
notched and individuals involved in dosing assigned mice a unique identification code and
randomly assigned mice to test or control groups. A sample size of n = 11 for test groups was
determined as minimally adequate to detect a�90% average reduction in adult male O.
ochengi worm burden with>80% power, based on prior variation in worm burden recovery
rate in untreated or vehicle dosed SCID mice (mean % recovery = 29.07, s.d. = 20.1) [33, 36].
A group size of n = 5 for test groups was determined as minimally adequate to detect�70%
average reduction in circulating Bmmf 2 days following treatment based on prior variation in
microfilaraemias per millilitre of tail vein blood in vehicle dosed SCID mice (mean mf/
ml = 242, s.d. = 225) [33]. O. ochengi implanted mice from an individual donor source (each
individual cow) were distributed evenly within each treatment / control group to minimize
bias due to inter-donor variation and/or experimental variation in daily isolations potentially
affecting long-term adult O. ochengi viability. For O. ochengi testing, two experiments (A and
B) were conducted. In experiment A there was one untreated (negative) control group (n = 11)
and a positive control group was included in which FBZ was administered SC by injection at
10 mg/kg once per day (QD) for 5 consecutive days (n = 6 mice). In experiment B, there was
one vehicle (negative) control group (n = 11). For B. malayi testing, one vehicle (negative) con-
trol group and one positive control group was included where IVM was administered OR at
0.2 mg/kg once (both n = 5). Dosing for all experiments is listed in Table 1.
Individuals involved in randomisation were also involved in dosing and were thus
unblinded to treatment. Individuals responsible for evaluating primary and secondary efficacy
readouts were blinded as to treatment group.
Pharmacokinetic sampling and analysis
For all treated groups blood was collected for pharmacokinetic analysis. A plasma profile was
sampled on the final day of dosing (or on the day of dosing for single dose SC groups). SC
groups were continuously sampled after dosing by one sample per week until necropsy. For
Preclinical testing of oral flubendazole as an Onchocerciasis macrofilaricide
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each time point, 3 animals per group were sampled, using a micro-sampling technique. Each
animal was sampled a maximum of twice per day. The exact time of sampling was recorded
for each sample. Approximately 20μl blood was collected per animal from the tail vein, using
EDTA-coated Microvette1 CB 300 K2E tubes (Sarstedt). Blood was placed immediately on
ice prior to centrifugation. After centrifugation (1900�g for 10 min) 10μl plasma was trans-
ferred into a 0.5 ml Eppendorf tube and placed immediately at -20˚C. All plasma samples were
shipped on dry ice to Janssen Beerse via Liverpool School of Tropical Medicine in a single
batch at the end of the study. Analysis of the plasma samples was done at PD&S-PDM regu-
lated bioanalysis department (J&J PRD, Beerse). Plasma samples were analysed for JNJ-161941
(FBZ) and the metabolites JNJ-1809600 (R-FBZ) and JNJ-114699 (H-FBZ) using a qualified
LC-MS/MS method. The following pharmacokinetic parameters were calculated: Cmax, Tmax,
and AUC values. Dose-proportionality was evaluated. The plasma curves were prepared in the
same matrix as the plasma study samples. For each analytical run QC samples were analysed
together with the study samples and calibration curve. All analytical batches were accepted
based on calibration curve and QC acceptance criteria in line with the current FDA guidelines.
A limited pharmacokinetic analysis on the mean plasma concentrations was performed using
Phoenix™ Professional (Version 6.2.1). A non-compartmental analysis using the lin/log trape-
zoidal rule with lin/log interpolation was used for all data.
For simulating PK profiles of different dosing regimes, the PK data was fitted using a two
compartment model for the SC formulations and a one compartment model for OR prepara-
tions. PK parameters were generated for each experimental arm using ADAPT 5 (Biomedical
Simulations Resource–University of California). The PK parameters were then then used to
generate simulations for different dosing scenarios using the ADAPT 5 simulator. For PK
analysis SC and ORl data were fitted using the following equations.
dX1
dt
¼   ka � X1
dX2
dt
¼ ka � X1   kcp þ ke
� �
� X2 þ kpc � X3
dX3
dt
¼ kcp � X2   kpc � X3
Table 1. Dose groups for oral FBZ testing.
EXPT Group n Dosing regimen Route Formulation Volume / kg Dose (mg/kg)
Experiment A: Male Onchocerca implants A1 11 untreated control
A2 6 QD 5x SC FBZ HEC/Tween 10ml 10
A3 11 QD 5x OR FBZ bend 1/9 10ml 0.2
A4 11 QD 5x OR FBZ bend 1/9 10ml 1.5
A5 11 QD 1x SC FBZ HEC/Tween 10ml 10
Experiment B: Male Onchocerca implants B1 10 QD 5x OR vehicle control 10 ml 0
B2 11 QD 5x OR FBZ bend 1/9 10 ml 15
B. malayi mf infusions 1 5 Single oral dose OR Vehicle control
2 5 Single oral dose OR IVM 10ml 0.2
3 5 Single oral dose OR FBZ bend 1/9 10ml 2
4 5 Single oral dose OR FBZ bend 1/9 10ml 40
https://doi.org/10.1371/journal.pntd.0006356.t001
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C ¼
X2
V
Where X1 represents the drug mass in dosing compartment, X2 represents drug mass in the
systemic circulation and X3 represents the drug mass peripheral compartment. ka represents
the rate of absorption (h-1), ke the rate of drug elimination (h-1), kcp and kpc the rates of transfer
between the central and peripheral compartments (h-1), V represents the volume of distribu-
tion (mL) and C is the concentration of drug at any given time (mg/L).
For the OR preparations, a one compartment model was sufficient to fit the data as evi-
denced by AIC and BIC parameters as well as the intercompartmental transfer rates being neg-
ligible. For these reasons, the parameters kcp and kpc were fixed to zero to fit the oral data into a
one compartment model.
Adult O. ochengi parasite recovery and motility assay post-treatment
Mice were euthanized by UK Home Office approved schedule 1 method at 5 weeks post-first
dose administration. The primary efficacy parameter was the worm burden of live male
worms recovered after necropsy from the abdominal cavity, including visceral connective tis-
sues. As secondary readout, cure rate (number of mice without active infection) was also evalu-
ated. As a further secondary readout, motility scoring of recovered adult male O. ochengi
parasites was determined by visual inspection after 15 minutes in culture in 37˚C RPMI post-
recovery, including motility in response to gentle prodding with a blunt pipette. A semi-quan-
titative score for worm motility was applied. Worms that showed no motility were counted as
‘0’ = immotile, ‘1’ = only anterior or posterior twitching motility ‘2’ = reduced sigmoidal motil-
ity ‘3’ = full sigmoidal motility.
MTT-formazan reduction colourmetric assay
As an additional secondary readout, male O. ochengi recovered at necropsy were washed in
PBS and individually placed in a solution of MTT in PBS, final concentration 0.5 mg/ml, incu-
bated for 2 hours at 37˚C with 5% CO2. After washing in PBS, the O. ochengi were incubated
in 100% DMSO for 1 hour at 37˚C with 5% CO2 to dissolve and release the blue formazan
product. The samples were read at OD 490 nm.
B. malayi microfilaraemia quantifications
For primary efficacy readout the number of circulating mf were enumerated by tail vein
scratch sampling method and collection of 2x20μl fresh blood aspirated by Gilson pipette at
baseline and 2 days post-treatment. For secondary readout, mice were euthanized by UK
Home Office approved schedule 1 method at 7 days post-treatment. A 40μl blood volume was
collected by cardiac puncture immediately after cullling. Immediately after blood collections,
volumes were spread onto uncoated glass slides to make air-dried thick smear preparations.
Briefly blood was collected either from the tail vein (2x20μL, as for peripheral blood microfilar-
emia) or from the heart (2x30μL at necropsy using a 25G 1mL syringe, as for cardiopulmonary
microfilaremia) and transferred onto a glass slide and then processed for a thick smear
through a scratch method. Resulting smear was left to dry then slides were incubated in dis-
tilled water for 4min to lyse erythrocytes, fixed in methanol for 1min and finally stained with
40% Giemsa for 40min followed by a wash in distilled water until clear. Total numbers of
Bmmf were counted per two replicate slides by microscopy and adjusted (x25) to obtain a
parasitaemia per millilitre of blood. Of the 120 thick blood smears evaluated, 10% (n = 12)
Preclinical testing of oral flubendazole as an Onchocerciasis macrofilaricide
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were independently re-assessed by a scientist not directly involved in the study and percentage
variance was determined as<20% for all samples (mean = 10.3%,+/-5.59% S.D.).
Statistical analysis
For primary readout analysis of O. ochengi worm recovery, a dose/schedule providing a reduc-
tion in average worm burden of�90% versus the control group was considered as efficacious.
The percent effectiveness was calculated using geometric mean (GM) as follows:
%eff icacy ¼
GM untreated group  GM dose group
GM untreated group
X100;
where GM is a geometric mean of the number of male O. ochengi recovered at 5 weeks post-
treatment for each group. Since the number of recovered male O. ochengi at 5 weeks post-treat-
ment was zero for some animals, a value of 0.1 was added to each data for the calculation of
the GM. Number of male O. ochengi recovered at 5 weeks post-treatment (+0.1) for both
experiments were examined for normality, using the Shapiro-Wilk test [37]. The data failed to
pass this test. Therefore, data was log10 transformed and the transformed data was tested for
normality as before. The log10 transformed data did not satisfy the Shapiro-Wilk test for nor-
mality. Therefore, Kruskal-Wallis non-parametric test was used to compare the groups in
experiment A and followed by post-hoc Dunn’s test [38] to compare each dose group to the
untreated group. The Mann Whitney non-parametric test was used on the original raw data to
compare the two groups in experiment B.
For primary readout analysis of Bmmf in the peripheral circulation, a dose/schedule provid-
ing a reduction in average worm burden of�70% versus the vehicle control group 2 days after
dosing was considered as efficacious as a rapid microfilaricide. The efficacy of a test group was
calculated as following:
%effectiveness ¼
100 ðGM microfilariaemia baseline   GM microfilariaemiaþ 48hÞ
GM microfilariaemia baseline
For changes in peripheral microfilaraemias, change was calculated as follows:
delta peripheral mf=ml ¼ mf=ml atþ 2 days orþ 7 days   mf=ml baseline:
Delta peripheral mf/ml at +2 day and cardiopulmonary circulating mf/ml +7 days post-
treatment continuous variable distributions were examined for normality by the Shapiro-Wilk
test. Data that was not normally distributed was then log10 transformed before being re-tested
for normality. All raw data or log10-transformed data did not deviate from a normal distribu-
tion pattern. Therefore, 1 Way ANOVA with Dunnett’s tests were applied to examine signifi-
cant differences between vehicle and drug groups in delta peripheral mf/ml at +2 days and
Log10 cardiac mf/ml at +7 days post-treatment. All tests were performed at a significance level
of 5%.
Additional efficacy parameters analysed in both O. ochengi experiment A and B were: 1. fre-
quency of animals with zero worm count / group (cure rate) 2. the frequency of mice with nor-
mal vs reduced motile male O. ochengi present at necropsy 3. the metabolic activity of motile
male O. ochengi retrieved at necropsy. The proportions of mice with or without infection were
expressed as percentages of the total group number. Raw data (numbers of infected and unin-
fected mice) were compared for each group in a 5x2 contingency table and tested for signifi-
cance by Chi-square Test. Post-hoc tests were undertaken comparing control against specific
treatment groups by 2x2 contingency tables and two-tailed Fisher’s Exact Tests. For O. ochengi
metabolic activity, formazan optical densities from worm extractions were averaged (mean)
Preclinical testing of oral flubendazole as an Onchocerciasis macrofilaricide
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per mouse in each group, measured by MTT-formazan reduction colourmetric assay. Mean O.
ochengi metabolic activity data was checked for normality, using the Shapiro-Wilk test. Subse-
quently, 1 Way ANOVA with post-hoc Dunnett’s Tests were used to determine significance
between control and treated groups of mice. All tests were performed at a significance level of 5%.
Results
Assessment of O. ochengi worm burden 5 weeks post-dosing with FBZ
Raw data for numbers of O. ochengi recovered per mouse / treatment are plotted in Fig 1 for
both experiment A and B. Table 2 details the geometric means (95% confidence intervals) of
raw data +0.1 and the derived calculated percentage efficacy for both experiments.
Multiple injected FBZ (10mg/kg) mediated a high level of efficacy against male O. ochengi
(92.9%) and single injection (10mg/kg) also mediated substantial efficacy (82%). Oral dosing
of FBZ did not emulate the efficacy of injections (0%, 19% and 29.9% for 0.2, 1.5 and 15mg/kg,
respectively) (Table 2). Subsequently, the statistical variation between numbers of male O.
Fig 1. O. ochengi male worm burdens 5 weeks following indicated treatments for experiments (A) and (B). Bars are
median recovered numbers per group. Treatment with s.c. injected FBZ 10mg/kg qd 5x mediated a significant
reduction in the retrieval of viable O. ochengi worms (Kruskal-Wallis ANOVA = 15.45, Dunn’s tests untreated vs FBZ
10mg/kg qd 5x P<0.05�).
https://doi.org/10.1371/journal.pntd.0006356.g001
Table 2. O. ochengi treatment efficacy post-FBZ dosing.
Group Treatment n Geometric mean
+5 weeks (95% CI)
% efficacy
A1� untreated 11 2.11 (1.74–4.65) -
A2 FBZ 10mg/kg QD 1x SC 10 0.38 (0–2.87) 82.0
A3 FBZ 10mg/kg QD 5x SC 6 0.15 (0–0.70) 92.9
A4 FBZ 0.2mg/kg QD 5x OR 11 2.93 (1.98–5.13) 0
A5 FBZ 1.5mg/kg QD 5x OR 11 1.71 (1.46–4.55) 19.0
B1� vehicle 10 5.2 (3.8–6.6) -
B2 FBZ 15mg/kg QD 5x OR 11 3.65 (2.88–4.41) 29.9
�A = O. ochengi adult implant experiment A, B = O. ochengi adult implant experiment B
https://doi.org/10.1371/journal.pntd.0006356.t002
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ochengi recovered at 5 weeks post-dosing was scrutinised (Fig 1). Multiple injected FBZ
(10mg/kg) significantly reduced worm burden compared with untreated controls (Fig 1A).
Variation in worm burdens in all other groups were not significantly different than untreated
controls (Fig 1A & 1B).
Frequency of mice with male O. ochengi present five weeks post-dosing
with FBZ
Table 3 details the proportions of mice in each dosing group that did not contain viable male
O. ochengi at necropsy (cure rate) for both experiments.
Motility assessments of male O. ochengi five weeks post-dosing with FBZ
Table 4 details the frequencies of normal or reduced motile worms five weeks post-dosing.
Table 3. O. ochengi cure rates post-FBZ dosing.
Group Treatment n n positive n negative cure rate
(%)
A1� | untreated 11 10 1 9.1
A2 FBZ 10mg/kg^
QD 1x SC
10 4 6 60
A3 FBZ 10mg/kg#
QD 5x SC
6 1 5 83.3
A4 FBZ 0.2mg/kg
QD 5x OR
11 11 0 0
A5 FBZ 1.5mg/kg
QD 5x OR
11 9 2 18.2
B1� vehicle 10 9 1 10
B2 FBZ 15mg/kg
QD 5x OR
11 10 1 9.1
�A = O. ochengi adult implant experiment A, B = O. ochengi adult implant experiment B
|Experiment A, 2x5 Chi-square, df 20.68, P = 0.0004���
^Fisher’s Exact Test (vs untreated), P = 0.0237�
#Fisher’s Exact Test (vs untreated), P = 0.0054��
https://doi.org/10.1371/journal.pntd.0006356.t003
Table 4. O. ochengi motility assessments post-FBZ dosing.
Group Treatment n n of animals with motile O. ochengi Total n motile O. ochengi assessed n O. ochengi normal/reduced motility
A1�# untreated 11 10 32 21/11
A2 FBZ 10mg/kg QD 1x SC 10 4 12 10/2
A3 FBZ 10mg/kg
QD 5x SC
6 1 1 0/1
A4 FBZ 0.2mg/kg 5x OR 11 11 36 30/6
A5 FBZ 1.5mg/kg QD 5x OR 11 9 29 16/13
B1�^ vehicle 10 9 47 33/14
B2 FBZ 15mg/kg
QD 5x OR
11 10 38 16/22
�A = O. ochengi adult implant experiment A, B = O. ochengi adult implant experiment B
#2x5 Chi-square, df 9.73, P = 0.0453
^Fisher’s Exact Test (vs vehicle control), P<0.0001
https://doi.org/10.1371/journal.pntd.0006356.t004
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In experiment A, by 2x5 Chi-square analysis, a significant difference in frequency in fully
motile vs reduced motile O. ochengi was apparent between the groups. However, it was deter-
mined by post-hoc Fisher’s Tests, that none of the treatment groups displayed a significantly
different frequency motility level when compared with the untreated controls. In experiment B,
the FBZ 15mg/kg QD 5x OR regimen group displayed a significantly lower frequency of fully
motile O. ochengi males compared with the vehicle control (Fisher’s Exact Test P<0.0001).
Metabolic activity of motile male O. ochengi five weeks post-dosing with FBZ
Fig 2 details the metabolic activity of male O. ochengi in mice that contained viable, motile
worms five weeks post-dosing for both experiments. Motile worms isolated from single
injected FBZ treated mice displayed similar metabolic activity compared with untreated con-
trols. Further, motile O. ochengi recovered from multiple dosed oral FBZ mice (at 0.2 or
1.5mg/kg) did not show a significant reduction in metabolic activity compared with untreated
controls. However, in adult motile O. ochengi derived from mice treated with FBZ orally at
15mg/kg QD x5, the metabolic activity was significantly reduced compared with the matching
vehicle controls (unpaired T test, P = 0.0496).
Assessment of B. malayi microfilaraemias post-dosing with single oral dose
FBZ
Table 5 details the change in peripheral circulating microfilaraemias initially recorded at base-
line and at two days following single oral dose with the positive control IVM at 0.2mg/kg
Fig 2. Average O. ochengi metabolic activity per mouse where motile worms were present, five weeks post-dosing with indicated
treatments for experiment A (A) or B (B). Data points are mean formazan optical densities @490nm from worms recovered from
each animal. Bars are mean +/-SEM per treatment group. Variation between untreated and treatment groups in experiment A
was not significantly different (1way ANOVA). Metabolic activity was significantly reduced following FBZ oral 15mg/kg qd x 5
days (Unpaired T-test, �P<0.05) in experiment B.
https://doi.org/10.1371/journal.pntd.0006356.g002
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compared with FBZ at 2 or 40mg/kg. Only IVM mediated a significant, 80.9% rapid reduction
in circulating levels of Bmmf. In comparison, the change in peripheral circulating mf following
low or high dose FBZ were not significantly different to reductions evident in the vehicle con-
trol group (11.8% and 49% efficacy, 2 and 40mg/kg, respectively, vs 37.5%, vehicle).
After seven days following treatment, the level of B. malayi mf in cardiac blood was assessed
following necropsy (Fig 3). The geometric mean level of microfilaraemia in vehicle treated ani-
mals was 8236mf/ml (985–19486 95% C.I.). Single dose IVM-treated animals had a signifi-
cantly reduced burden of microfilaraemia (84.7% efficacy, 1way ANOVA F = 4.6, P = 0.019,
P<0.05, vehicle vs IVM, Dunnett’s post-hoc test). In comparison the levels of parasitaemias in
low or high single doses of FBZ were not significantly reduced compared with vehicle.
Pharmacokinetic analysis and modelling
For all experiments, the plasma concentrations and pharmacokinetics parameters of FBZ,
H-FBZ and R-FBZ are depicted in Table 6. After single subcutaneous administration of FBZ to
male SCID mice at 10mg/kg, peak plasma concentrations were observed 1hr after dosing.
After multiple oral administration of FBZ to male SCID mice for 5 days, peak plasma concen-
trations at day 5 were observed at 0.5hr after dosing at 0.2 and 1.5mg/kg, and at 1hr after dos-
ing at 15mg/kg, suggesting a rapid absorption. Cmax and AUClast values increased dose
proportionally. In experiment A, the R-FBZ/FBZ ratio ranged from 0.1 to 0.4 and from 0.3 to
0.7 for H-FBZ/FBZ across all FBZ dosed groups. In experiment B, the R-FBZ/FBZ ratio was
0.4, the H-FBZ/FBZ ratio was 0.55.
After single administration of FBZ to male SCID mice at 2 and 40 mg/kg, peak plasma con-
centrations were observed at 0.5hr after dosing, suggesting a rapid absorption. Cmax and
AUCinf values increased less than dose proportionally to the dose between 2mg/kg/day up to
40mg/kg. In this latter study the R-FBZ/FBZ ratio ranged from 0.4 to 0.6 and from 0.4 to 0.5
for H-FBZ/FBZ across both FBZ dosed groups. The PK exposures of parental FBZ and its
major metabolites FBZ-R and FBZ-H at the highest oral dose (15mg/kg QD 5x) or the injected
dose (10mg/kg QD 5x) were simulated and compared with one another using a PK modelling
approach (Fig 4 & S1 Data). From these simulations, an oral dose regimen that more closely
emulated the exposure profile of multiple injected FBZ was determined as 0.2 mg/kg QID for
35 days.
Discussion
FBZ has been proposed as a relatively ‘low hanging fruit’ to reformulate and repurpose as an
oral Onchocerca macrofilaricide [24, 39]. Delivered as a multiple injection, FBZ is highly
Table 5. Change in peripheral B. malayi microfilaraemias two days after single oral FBZ.
group Geometric mean baseline
(95% CI)
Geometric mean +2d
(95% CI)
% efficacy +2d
Vehicle 1572
(1000–2471)
982
(672–1435)
37.5
IVM 0.2mg/kg# 2041
(1651–2523)
388
(278–543)
80.9
FBZ 2mg/kg 1284
(1069–1541)
1133
(640–2005)
11.8
FBZ 40mg/kg 1806
(1034–3156)
921
(432–1961)
49.0
#1 way ANOVA (F = 5.812, P = 0.007) with Dunnett’s tests post-hoc (vehicle vs IVM, P<0.05).
https://doi.org/10.1371/journal.pntd.0006356.t005
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potent in mediating rapid death of O. ochengi [33] and O. volvulus in vivo [24, 32]. Addition-
ally, as with other members of the benzimidazole (BZ) class, FBZ is more efficacious at target-
ing adult Onchocerca rather than Onchocerca mf [24, 40], making it an attractive option for an
indication where rapid microfilaricidal activity would want to be avoided (e.g. areas of L. loa
co-endemicity).
Selective toxicity stems from BZ binding to nematode β tubulin with approximately 10-fold
greater affinity than mammalian tubulin, principally due to polymorphisms around amino
acid position 200. Efficacy appears to be most readily manifest in embryotoxic effects on
Fig 3. Average B. malayi microfilariaemias in cardiac blood seven days post-dosing with indicated treatments.
Data points are microfilariaemias per mouse. Bars are mean +/-SEM per treatment group. Variation between
untreated and treatment groups was significantly different (1way ANOVA F = 4.6, P = 0.019). Significant differences
compared with vehicle controls, evaluated by Dunnett’s tests, are indicated � (P<0.05).
https://doi.org/10.1371/journal.pntd.0006356.g003
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female worms, whereby prevention of microtubule elongation interferes with chromosome
segregation and mitotic cell division, leading to defective embryogenesis. A fecund female
intra-nodular Onchocerca small animal model is currently not available to scrutinise this spe-
cific impact of oral FBZ, which may be potentially delinked from macrofilaricidal activity (i.e.
sterilising activity only). However, surrogate filarial models of onchocerciasis (Brugia pahangi
and Litomosoides sigmodontis gerbil infection models) allow for scrutiny of embryogenesis
post-drugging. Efficacy testing with oral FBZ at matching doses has been undertaken in these
lymphatic filarial infection models by independent laboratories and their findings will be pub-
lished elsewhere.
Beyond targeting the female germline, other rapidly dividing filarial cells would also pre-
sumably be sensitive to the β tubulin capping and subsequent mitosis blocking effects of FBZ.
Indeed, histopathological evidence suggests intestinal and hypodermal tissue abnormalities are
rapidly manifest after brief in vitro exposure of adult filariae to FBZ [41]. Furthermore, multi-
ple injections target male worms in vivo [33].
Three concerns have been raised over the development of FBZ as a macrofilaricide: First,
the parenteral route of administration is not compatible with a field-based NTD indication
and intra-muscular injections cause undesirable inflammatory adverse reactions at the injec-
tion site. Second, FBZ is poorly bioavailable when given orally. The third concern is that FBZ
has a narrow safety margin before deleterious effects on mammalian cell division, which may
lead to carcinogenic toxicity, are detected in preclinical toxicological assays.
Addressing the first two caveats, we have been successful in developing an orally-bioavail-
able formulation of FBZ. Sparse PK measurements taken in SCID mice dosed during our
infection experiments demonstrate that rapid and dose-proportional absorption occurred
after oral dosing with the FBZ Bend 1/9 formulation, confirming previous rich PK measure-
ments. The PK profile of the multiple oral administered FBZ displayed a distinct profile com-
pared with that of subcutaneous injections. Whilst oral dosing mediated upwards of>50 fold
higher Cmax of the active FBZ-R than achievable with injections, the injected FBZ gave a sus-
tained chronic exposure of FBZ-R over 35 days of exposure.
We hypothesized that the high Cmax obtained following oral dosing would mitigate
against the much-reduced systemic half-life of the active FBZ-R metabolite in mediating
Table 6. FBZ pharmacokinetic parameters following 5 days of dosing.
Group Day Treatment Cmax
|
(μg/mL)
tmax
^
(h)
terminal t1/2ℵ (h) AUClast # (μg.h/mL) H-FBZ /FBZ AUC ratio R-FBZ/FBZ AUC ratio
A2 5 10mg/kg QD 5x SC 0.04 3 648 9.9 0.6 0.2
A3 1 10mg/kg QD 1x SC 0.07 1 332 5.3 0.3 0.1
A4 5 0.2mg/kg QD 5x OR 0.03 0.5 4 0.12 0.4 0.2
A5 5 1.5mg/kg QD 5x OR 0.3 0.5 0.5 0.72 0.7 0.4
B2 5 15mg/kg QD 5x OR 2.91 1.0 2 10.3 0.55 0.40
C3 1 2mg/kg
1x OR
0.4 0.5 2 1.4 0.5 0.4
C4 1 40mg/kg
1x OR
3.7 0.5 3.5 14 0.4 0.6
�A = O. ochengi adult implant experiment A, B = O. ochengi adult implant experiment B, C = B. malayi mf infusion experiment
|Cmax: highest observed plasma concentration
^tmax: time point when Cmax is observed
#AUClast: Area Under the plasma concentration vs. time curve (last: last time point where plasma concentration is measured); H-FBZ: hydrolysed FBZ; R-FBZ: reduced
FBZ
ℵ terminal t1/2: Apparent terminal elimination half-life (estimated graphically from simulated PK profiles)
https://doi.org/10.1371/journal.pntd.0006356.t006
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macrofilaricidal activity. However, initial in vivo testing with 0.2 or 1.5 mg/kg dosing for five
days did not achieve any notable adulticidal activity against implanted O. ochengi male worms
(0 & 19% efficacy, respectively) nor was there any significant indication of reduced viability of
O. ochengi retrieved from SCID mice 35 days after dosing. When elevating the dose to 15 mg/
kg, a sub-optimal 30% efficacy was recorded with partial yet significant reductions in viability
assays of the retrieved O. ochengi parasites at +35 days. Because filariae with reduced viability
following short high dose FBZ exposures (24 hour, 10μM) can recover after washout in vivo,
the partially reduced metabolic activity detected following 15mg/kg oral treatment may reflect
a temporary and reversible drug effect [41]. This was in marked contrast to parenterally-deliv-
ered FBZ which achieved 82% macrofilaricidal efficacy after a single injection. Confirming our
previous observations [33], multiple injections were still required to deliver>90% efficacy
against adult O. ochengi. Further oral dose elevations beyond 15mg/kg for 5 days were ruled
out in this preclinical model due to toxicological findings indicating a negative safety window
at or beyond this dose level. Using PK modelling we show that to maintain FBZ levels consis-
tent to those observed in efficacious SC dosing, a 4 time daily dosing of 0.2mg/kg of the oral
formulation over 35 days is needed. Such a dosing regime would maintain FBZ levels above
Fig 4. Comparison between oral PK profile (dashed red lines) and s.c. injection PK profile (solid black line) in CB. 17 SCID mice as assessed from PK
modelling of exposure data. (Top left) FBZ PK after 10mg/kg qd 5x s.c. FBZ or 15mg/kg qd 5x oral FBZ. (Top right) H-FBZ PK after 10mg/kg qd 5x s.c. FBZ
or 15mg/kg qd 5x oral FBZ. (bottom left) R-FBZ PK after 10mg/kg qd 5x s.c. or 15mg/kg qd 5x oral FBZ. (bottom right) Simulated FBZ PK profile after 10mg/
kg qd 5x s.c. or 5 week, 4 times daily (qds) regimen of 0.5mg/kg oral FBZ.
https://doi.org/10.1371/journal.pntd.0006356.g004
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those obtained from 10mg/kg QD 5x SC for at least 80% of the whole duration of treatment.
The need for multiple dosing per day is due to the oral formulation’s short half-life (~2h). The
most likely reason for the longer exposure achieved by SC administration of FBZ is its slow
absorption across the subcutaneous barrier which creates a depot effect allowing for the drug
to be released steadily over a period of>35 days.
We coincidently tested whether oral FBZ and its metabolites impacted on circulating B.
malayi mf in the blood (as a surrogate bloodborne microfilarial model of L. loa). The rationale
for this was to evaluate any potential safety risk of oral FBZ mediating rapid ‘IVM-like” micro-
filaricidal activity. Despite the increased peak plasma concentration of the oral formulation,
we did not identify any evidence that FBZ was directly microfilaricidal and conclude that ele-
vated exposures of this BZ drug are not likely to mediate substantial rapid activity against
bloodborne mf.
In conclusion, oral dosing with the FBZ Bend 1/9 formulation achieves bioavailability of
FBZ and its active metabolite but does not confer significant macrofilaricidal activity against
adult O. ochengi nor significant microfilaricidal activity against bloodborne mf in the pan-filar-
ial SCID mouse in vivo models utilised. Efficacy is not driven by Cmax but rather by sustained
drug levels over long periods of time as indicated by the discrepancy between the terminal
half-life of FBZ when administered subcutaneously (apparent terminal t1/2 up to 648h) and
when administered orally (apparent terminal t1/2 0.5h-4h). This discrepancy can be further
appreciated by comparing the simulated exposure profiles of FBZ when administered orally
and subcutaneously at similar doses. Evidently, the markedly higher initial levels of drug in the
oral formulations (~70-fold higher Cmax) are redundant in terms of producing superior phar-
macological activity. A prolonged exposure lasting for ~35 days however, even at peak concen-
trations that are ~70-fold lower than what is observed in current oral profiles could achieve
better macrofilaricidal efficacy. Either a sustained release formulation or prolonged oral dosing
durations would be necessary to achieve matching efficacious exposure to injection routes but
caution in this approach would be necessary given the low safety window determined for this
drug.
Supporting information
S1 Data. Results of compartmental PK analysis as determined from PK modelling of FBZ
exposure data.
(DOCX)
Author Contributions
Conceptualization: Marc Engelen, Benny Baeten, Stephen A. Ward, Mark J. Taylor, Samuel
Wanji, Joseph D. Turner.
Data curation: Nicolas Pionnier, Marc Engelen, Samuel Wanji.
Formal analysis: Hanna T. Sjoberg, Nicolas Pionnier, Ghaith Aljayyoussi, Haelly M. Metuge,
Sophie Lachaud, Fetene Tekle, Ludo Quirynen, Joseph D. Turner.
Funding acquisition: Mark J. Taylor, Samuel Wanji, Joseph D. Turner.
Investigation: Hanna T. Sjoberg, Nicolas Pionnier, Haelly M. Metuge, Abdel J. Njouendou,
Valerine C. Chunda, Fanny F. Fombad, Dizzle B. Tayong, Narcisse V. T. Gandjui, Des-
mond N. Akumtoh, Patrick W. N. Chounna, Bertrand L. Ndzeshang, Sophie Lachaud,
Fetene Tekle, Ludo Quirynen, Andrew Steven, Joseph D. Turner.
Preclinical testing of oral flubendazole as an Onchocerciasis macrofilaricide
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006356 January 16, 2019 16 / 19
Methodology: Hanna T. Sjoberg, Nicolas Pionnier, Ghaith Aljayyoussi, Haelly M. Metuge,
Sophie Lachaud, Fetene Tekle, Ludo Quirynen, Samuel Wanji, Joseph D. Turner.
Project administration: Ludo Quirynen, Marc Engelen, Benny Baeten, Samuel Wanji, Joseph
D. Turner.
Resources: Ludo Quirynen, Marc Engelen, Benny Baeten, Andrew Steven, Stephen A. Ward,
Mark J. Taylor, Joseph D. Turner.
Supervision: Samuel Wanji, Joseph D. Turner.
Writing – original draft: Hanna T. Sjoberg, Ghaith Aljayyoussi, Joseph D. Turner.
Writing – review & editing: Nicolas Pionnier, Marc Engelen, Benny Baeten, Samuel Wanji,
Joseph D. Turner.
References
1. Meeting of the International Task Force for Disease Eradication, January 2014. Wkly Epidemiol Rec.
2014; 89(15):153–60. PMID: 24754045
2. Bockarie MJ, Kelly-Hope LA, Rebollo M, Molyneux DH. Preventive chemotherapy as a strategy for elim-
ination of neglected tropical parasitic diseases: endgame challenges. Philos Trans R Soc Lond B Biol
Sci. 2013; 368(1623):20120144. https://doi.org/10.1098/rstb.2012.0144 PMID: 23798692
3. Taylor MJ, Hoerauf A, Bockarie M. Lymphatic filariasis and onchocerciasis. Lancet. 2010; 376
(9747):1175–85. https://doi.org/10.1016/S0140-6736(10)60586-7 PMID: 20739055
4. [APOC] APfOC. Final communique´ Joint Action Forum (JAF) of APOC; Paris, France2005.
5. WHO. Onchocerciasis Factsheet No 374. 2016.
6. WHO. Onchocerciasis and its control: Report of a WHO Expert Committee on Onchocerciasis Control.
1995.
7. African Programme for Onchocerciasis Control—report of the sixth meeting of National Task Forces,
October 2009. Wkly Epidemiol Rec. 2010; 85(4):23–8. PMID: 20095110
8. Turner JD, Langley RS, Johnston KL, Gentil K, Ford L, Wu B, et al. Wolbachia lipoprotein stimulates
innate and adaptive immunity through Toll-like receptors 2 and 6 to induce disease manifestations of fil-
ariasis. J Biol Chem. 2009; 284(33):22364–78. https://doi.org/10.1074/jbc.M901528200 PMID:
19458089
9. Pearlman E, Hall LR, Higgins AW, Bardenstein DS, Diaconu E, Hazlett FE, et al. The role of eosinophils
and neutrophils in helminth-induced keratitis. Invest Ophthalmol Vis Sci. 1998; 39(7):1176–82. PMID:
9620077
10. Remme JHF, Feenstra P, Lever PR, Medici AC, Morel CM, Noma M, et al. Tropical Diseases Targeted
for Elimination: Chagas Disease, Lymphatic Filariasis, Onchocerciasis, and Leprosy. In: Jamison DT,
Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, et al., editors. Disease Control Priorities
in Developing Countries. 2nd ed. Washington (DC)2006.
11. WHO. Global Plan to Combat Neglected Tropical Diseases 2008–2017 2007 [Available from: http://
apps.who.int/iris/bitstream/10665/69708/1/WHO_CDS_NTD_2007.3_eng.pdf.
12. WHO. Accelerating Work to Overcome the Global Impact of Neglected Tropical Diseases: A Roadmap
for Implementation 2012 [Available from: http://www.who.int/neglected_diseases/NTD_RoadMap_
2012_Fullversion.pdf.
13. Dunn C, Callahan K, Katabarwa M, Richards F, Hopkins D, Withers PC Jr., et al. The Contributions of
Onchocerciasis Control and Elimination Programs toward the Achievement of the Millennium Develop-
ment Goals. PLoS Negl Trop Dis. 2015; 9(5):e0003703. https://doi.org/10.1371/journal.pntd.0003703
PMID: 25996946
14. Molyneux DH, Bradley M, Hoerauf A, Kyelem D, Taylor MJ. Mass drug treatment for lymphatic filariasis
and onchocerciasis. Trends Parasitol. 2003; 19(11):516–22. PMID: 14580963
15. Cupp EW, Sauerbrey M, Richards F. Elimination of human onchocerciasis: history of progress and cur-
rent feasibility using ivermectin (Mectizan((R))) monotherapy. Acta Trop. 2011; 120 Suppl 1:S100–8.
16. Basanez MG, Pion SD, Churcher TS, Breitling LP, Little MP, Boussinesq M. River blindness: a success
story under threat? PLoS Med. 2006; 3(9):e371. https://doi.org/10.1371/journal.pmed.0030371 PMID:
17002504
Preclinical testing of oral flubendazole as an Onchocerciasis macrofilaricide
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006356 January 16, 2019 17 / 19
17. Evans DS, Alphonsus K, Umaru J, Eigege A, Miri E, Mafuyai H, et al. Status of Onchocerciasis trans-
mission after more than a decade of mass drug administration for onchocerciasis and lymphatic filaria-
sis elimination in central Nigeria: challenges in coordinating the stop MDA decision. PLoS Negl Trop
Dis. 2014; 8(9):e3113. https://doi.org/10.1371/journal.pntd.0003113 PMID: 25233351
18. Bourguinat C, Pion SD, Kamgno J, Gardon J, Duke BO, Boussinesq M, et al. Genetic selection of low
fertile Onchocerca volvulus by ivermectin treatment. PLoS Negl Trop Dis. 2007; 1(1):e72. https://doi.
org/10.1371/journal.pntd.0000072 PMID: 17989786
19. Osei-Atweneboana MY, Awadzi K, Attah SK, Boakye DA, Gyapong JO, Prichard RK. Phenotypic evi-
dence of emerging ivermectin resistance in Onchocerca volvulus. PLoS Negl Trop Dis. 2011; 5(3):
e998. https://doi.org/10.1371/journal.pntd.0000998 PMID: 21468315
20. Osei-Atweneboana MY, Boakye DA, Awadzi K, Gyapong JO, Prichard RK. Genotypic analysis of beta-
tubulin in Onchocerca volvulus from communities and individuals showing poor parasitological
response to ivermectin treatment. Int J Parasitol Drugs Drug Resist. 2012; 2:20–8. https://doi.org/10.
1016/j.ijpddr.2012.01.005 PMID: 24533268
21. Taylor MJ, Awadzi K, Basanez MG, Biritwum N, Boakye D, Boatin B, et al. Onchocerciasis Control:
Vision for the Future from a Ghanian perspective. Parasit Vectors. 2009; 2(1):7. https://doi.org/10.1186/
1756-3305-2-7 PMID: 19154624
22. Gardon J, Gardon-Wendel N, Demanga N, Kamgno J, Chippaux JP, Boussinesq M. Serious reactions
after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet.
1997; 350(9070):18–22. https://doi.org/10.1016/S0140-6736(96)11094-1 PMID: 9217715
23. Taylor MJ, Hoerauf A, Townson S, Slatko BE, Ward SA. Anti-Wolbachia drug discovery and develop-
ment: safe macrofilaricides for onchocerciasis and lymphatic filariasis. Parasitology. 2014; 141(1):119–
27. https://doi.org/10.1017/S0031182013001108 PMID: 23866958
24. Mackenzie CD, Geary TG. Flubendazole: a candidate macrofilaricide for lymphatic filariasis and oncho-
cerciasis field programs. Expert Rev Anti Infect Ther. 2011; 9(5):497–501. https://doi.org/10.1586/eri.
11.30 PMID: 21609260
25. Lacey E. The role of the cytoskeletal protein, tubulin, in the mode of action and mechanism of drug resis-
tance to benzimidazoles. Int J Parasitol. 1988; 18(7):885–936. PMID: 3066771
26. Bradley RE, Guerrero J, Becker HN, Michael BF, Newcomb K. Flubendazole: dose range and efficacy
studies against common internal parasites of swine. Am J Vet Res. 1983; 44(7):1329–33. PMID:
6881670
27. Horton RJ. Benzimidazoles in a wormy world. Parasitol Today. 1990; 6(4):106. PMID: 15463310
28. Kan SP. The anthelmintic effects of flubendazole on Trichuris trichiura and Ascaris lumbricoides. Trans
R Soc Trop Med Hyg. 1983; 77(5):668–70. PMID: 6659046
29. Yangco BG, Klein TW, Deresinski SC, Vickery AC, Craig CP. Flubendazole and mebendazole in the
treatment of trichuriasis and other helminthiases. Clin Ther. 1981; 4(4):285–90. PMID: 7332916
30. Denham DA, Samad R, Cho SY, Suswillo RR, Skippins SC. The anthelmintic effects of flubendazole on
Brugia pahangi. Trans R Soc Trop Med Hyg. 1979; 73(6):673–6. PMID: 538808
31. Mak JW. Antifilarial activity of mebendazole and flubendazole on Breinlia booliati. Trans R Soc Trop
Med Hyg. 1981; 75(2):306–7. PMID: 7303142
32. Dominguez-Vazquez A, Taylor HR, Greene BM, Ruvalcaba-Macias AM, Rivas-Alcala AR, Murphy RP,
et al. Comparison of flubendazole and diethylcarbamazine in treatment of onchocerciasis. Lancet.
1983; 1(8317):139–43. PMID: 6130195
33. Halliday A, Guimaraes AF, Tyrer HE, Metuge HM, Patrick CN, Arnaud KO, et al. A murine macrofilari-
cide pre-clinical screening model for onchocerciasis and lymphatic filariasis. Parasit Vectors. 2014;
7:472. https://doi.org/10.1186/s13071-014-0472-z PMID: 25338621
34. Ceballos L, Mackenzie C, Geary T, Alvarez L, Lanusse C. Exploring the potential of flubendazole in fila-
riasis control: evaluation of the systemic exposure for different pharmaceutical preparations. PLoS Negl
Trop Dis. 2014; 8(5):e2838. https://doi.org/10.1371/journal.pntd.0002838 PMID: 24874646
35. Longo M, Zanoncelli S, Messina M, Scandale I, Mackenzie C, Geary T, et al. In vivo preliminary investi-
gations of the effects of the benzimidazole anthelmintic drug flubendazole on rat embryos and fetuses.
Reprod Toxicol. 2014; 49:33–42. https://doi.org/10.1016/j.reprotox.2014.06.009 PMID: 24994687
36. Aljayyoussi G, Tyrer HE, Ford L, Sjoberg H, Pionnier N, Waterhouse D, et al. Short-Course, High-Dose
Rifampicin Achieves Wolbachia Depletion Predictive of Curative Outcomes in Preclinical Models of
Lymphatic Filariasis and Onchocerciasis. Sci Rep. 2017; 7(1):210. https://doi.org/10.1038/s41598-017-
00322-5 PMID: 28303006
37. Shapiro SS, Wilk MB. An analysis of variance test for normality (complete samples). Biometrika. 1965;
52(3–4):591–611.
38. Dunn JD. Multiple Comparisons Using Rank Sums. Technometrics. 1964; 6(3):241–52.
Preclinical testing of oral flubendazole as an Onchocerciasis macrofilaricide
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006356 January 16, 2019 18 / 19
39. Geary TG, Mackenzie CD. Progress and challenges in the discovery of macrofilaricidal drugs. Expert
Rev Anti Infect Ther. 2011; 9(8):681–95. https://doi.org/10.1586/eri.11.76 PMID: 21819332
40. Townson S, Dobinson A, Connelly C, Muller R. Chemotherapy of Onchocerca lienalis microfilariae in
mice: a model for the evaluation of novel compounds for the treatment of onchocerciasis. J Helminthol.
1988; 62(3):181–94. PMID: 3192910
41. O’Neill M, Geary JF, Agnew DW, Mackenzie CD, Geary TG. In vitro flubendazole-induced damage to
vital tissues in adult females of the filarial nematode Brugia malayi. Int J Parasitol Drugs Drug Resist.
2015; 5(3):135–40. https://doi.org/10.1016/j.ijpddr.2015.06.002 PMID: 26288741
Preclinical testing of oral flubendazole as an Onchocerciasis macrofilaricide
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006356 January 16, 2019 19 / 19
